Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | ATP4A | P20648 | 2/20 | 0.56 |
| ▸ | ATP4B | P51164 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9955024 | 0.82 | CYP19A1 (0.67) | CYP19A1ATP4AATP4BABL1MAPT | |
| SCHEMBL1804064 | 0.81 | MAPT (0.65) | CYP19A1ATP4AATP4BABL1MAPT | |
| SCHEMBL3765806 | 0.81 | CYP19A1 (0.60) | CYP19A1ATP4AATP4BABL1MAPT | |
| SCHEMBL28932584 | 0.79 | KDM4E (0.68) | MAPTRAB9AGAASMN1; SMN2CYP1A1 | |
| SCHEMBL982911 | 0.79 | RECQL (0.66) | CYP19A1ATP4AATP4BABL1MAPT | |
| SCHEMBL27703492 | 0.79 | TSHR (0.66) | MAPTRAB9AMAOANPC1GLA | |
| SCHEMBL3185335 | 0.78 | RAB9A (0.56) | CYP19A1ABL1MAPTRAB9AKDM1A | |
| SCHEMBL178051 | 0.77 | ALDH1A1 (0.61) | ATP4AATP4BMAPTRAB9ANPC1 | |
| SCHEMBL22815712 | 0.77 | ABL1 (0.52) | ABL1MAPTRAB9ANPC1GAA | |
| SCHEMBL12293307 | 0.76 | CYP19A1 (0.55) | CYP19A1ATP4AATP4BABL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1205472-B1 | Process for the preparation of dithiazolyldisulfides | BAYER AG (DE) | 2005-01-26 | — | — | EP | disclosed |
| US-6610857-B2 | Oxidation of 2-mercaptothiazoles with peroxidic compounds in an aqueous suspension | BAYER AKTIENGESELLSCHAFT (DE) | 2003-08-26 | — | — | US | disclosed |
| EP-1205472-A1 | Process for the preparation of dithiazolyldisulfides | BAYER AG (DE) | 2002-05-15 | — | — | EP | disclosed |
| US-20020055640-A1 | Process for the production of dithiazolyl disulfides | LANXESS DEUTSCHLAND GMBH (DE) | 2002-05-09 | — | — | US | disclosed |
| US-6248896-B1 | APPROPRIATELY SUBSTITUTED 2-MERCAPTOTHIAZOLE IS OXIDIZED WITH OXYGEN OR AN OXYGEN-CONTAINING GAS IN THE PRESENCE OF A SOLVENT AND A TERTIARY AMINE AND IRON HEMIPORPHYRAZINE. | BAYER AKTIENGESELLSCHAFT (DE) | 2001-06-19 | — | — | US | disclosed |
| US-6124467-A | Process for the preparation of dithiazolyl disulfides | BAYER AKTIENGESELLSCHAFT (DE) | 2000-09-26 | — | — | US | disclosed |
| EP-1008591-A1 | Process for the preparation of dithiazolyldisulfides | Bayer Aktiengesellschaft (DE) | 2000-06-14 | — | — | EP | disclosed |
| US-5124450-A | Reacting solution of 2-mercaptothiazole, saturated secondary heterocyclic amine, sulfur in presence of oxygen, ammonia, copper or cerium catalyst | AKZO N.V. (NL) | 1992-06-23 | — | — | US | disclosed |
| EP-0481366-A1 | Process for the preparation of 2-Aminodithiothiazoles and 2-Aminotrithiothiazoles | Akzo Nobel N.V. (NL) | 1992-04-22 | — | — | EP | disclosed |
| US-4558135-A | AMMONIA CATALYST | AKZONA INCORPORATED (US) | 1985-12-10 | — | — | US | disclosed |
| US-4307236-A | BY CATALYTIC OXIDATION OF 2-MERCAPTO THIAZOLES | AKZONA INCORPORATED (US) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055640-A1 | Process for the production of dithiazolyl disulfides | GPX4, PRDX3, PRDX2 | CYP19A1 3137/4885ATP4A 4428/4885ATP4B 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.